NYSE · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP
Conmed Corporation CNMD
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.4B
▲ 5.2% vs FY2024
EPS · FY25
$1.51
Dividend / sh · FY25
$0.60
Payout · FY25
53%
ROE · FY25
4.7%
Net margin · FY25
3.4%
Dividend coverage
2.5×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.4B
Revenue, FY2025 · full 17-year series below
Revenue
Net income
3 cents of every revenue dollar became profit this year.
Per share
USD 1.51
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 2.5 times — the rest stayed in the company.
Profitability
4.7%
Return on equity, FY2025
ROE
Operating margin7.5%
Net margin3.4%
Return on assets2.0%
Each USD of equity produced 5 cents of profit this year.
Returned to shareholders
USD 24.7M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 24.7M
Net buybacks—
Share of profit52.6%
Consecutive raises—
USD 24.7M in dividends — 53% of the year's profit went back to shareholders.
Growth
+9.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+9.6%
+9.8%
+6.7%
+4.5%
Net income
+37.7%
+4.4%
+3.0%
EPS, diluted
+36.4%
+3.3%
+2.5%
Dividend / share
−9.1%
−5.6%
−2.8%
Returned to shareholders
+1.1%
+1.6%
+1.1%
+1.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.3B
total assets, end of FY2025
Total assetsUSD 2.3B
EquityUSD 1.0B
CashUSD 40.8M
Gross debtUSD 834.2M
Net debtUSD 793.4M
Current ratio2.14×
Net debt stands at 77% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
1.4
1.3
1.2
1.0
1.0
0.9
1.0
0.9
0.8
0.8
0.7
0.7
0.8
0.8
0.7
0.7
0.7
Operating income $B
0.1
0.2
0.1
0.1
0.1
0.0
0.1
0.1
0.0
0.0
0.1
0.1
0.1
0.1
0.0
0.1
0.0
EBITDA $B
0.1
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.1
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
Net income $B
0.0
0.1
0.1
−0.1
0.1
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
1.51
4.25
2.04
−2.68
1.94
0.32
0.97
1.41
1.97
0.52
1.09
1.16
1.28
1.41
0.03
1.05
0.42
Dividend / sh $
0.60
0.80
0.80
0.80
0.80
0.80
0.80
0.80
0.80
0.80
0.80
0.80
0.65
0.60
0.00
0.00
·
Payout %
53
19
38
−30
37
240
79
55
40
151
72
68
46
32
0
0
·
ROE %
4.7
14.7
8.2
−10.5
8.4
1.3
4.2
6.3
9.2
2.5
5.2
5.4
5.9
6.9
0.1
5.2
2.1
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed